Cassyano J. Correr
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Cassyano J. Correr has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
- Antonio Matoso Mendes
Complexo Hospital de Clínicas da Universidade Federal do Paraná Curitiba Brasil
3 shared publications - Thaís Teles de Souza
Universidade Federal da Paraíba
3 shared publications - Angelita Cristine Melo
Departamento de Ciências Exatas e Biológicas, Campus Sete Lagoas, Universidade Federal de São João Del-Rei, Sete Lagoas 36307-352, Brazil
2 shared publications - Carla Serra2 shared publications
Conselho Federal de Farmácia
2 shared publications- Fernanda Stumpf Tonin
Pharmacy and Pharmaceutical Technology Department, Social and Legal Pharmacy Section, University of Granada, Granada, Spain
2 shared publications
Latest Publications
- Open Access
- 1 January 2022
- Published by Sociedade Brasileira de Cirurgia Cardiovascular in Brazilian Journal of Cardiovascular Surgery
- Vol. 37 (3) , 356-369
Cross-Cultural Translation into Brazilian Portuguese and Validation of the Oral Anticoagulation Knowledge Tool (AKT-Br)
Oral anticoagulants are the treatment of choice for diverse types of coagulation disorders. Warfarin is widely used by the Brazilian population, possibly due to its lower cost than other oral anticoagulants. However, it has a high risk of serious adverse effects if used incorrectly. The Anticoagulation Knowledge Tool (AKT) can assess a patient’s knowledge about her/his oral anticoagulant therapy and can assist health professionals in identifying patients with difficulties in adherence. This study aimed to translate, culturally adapt, and validate the AKT into Brazilian Portuguese. After a standard forward-backward procedure to translate the AKT into Brazilian Portuguese (AKT-Br), a version of the instrument was applied in three groups (patients, pharmacists, and the general population). The reliability of the AKT-Br was tested using an internal consistency measure and test-retest. The validity of the instrument was confirmed with data from the contrasted groups. All statistical analyses were performed with RStudio. The median scores obtained with the AKT-Br were 29.0, 17.0, and 7.5 for pharmacists, patients, and the general population, respectively (maximum score of 35 points). There was moderate internal consistency for the instrument and test-retest reliability was satisfactory. Analysis of variance for validity of the groups revealed a significant relationship between the total score and the evaluated groups. The ATK-Br is a reliable and valid tool to assess knowledge about oral anticoagulants. AKT-Br can be used in clinical practice as an auxiliary tool to improve patient care through personalised educational interventions.
- 1 January 2022
- Published by Sociedade Brasileira de Cirurgia Cardiovascular in Brazilian Journal of Cardiovascular Surgery
- Vol. 37 (3) , 356-369
Open AccessCross-Cultural Translation into Brazilian Portuguese and Validation of the Oral Anticoagulation Knowledge Tool (AKT-Br)
Oral anticoagulants are the treatment of choice for diverse types of coagulation disorders. Warfarin is widely used by the Brazilian population, possibly due to its lower cost than other oral anticoagulants. However, it has a high risk of serious adverse effects if used incorrectly. The Anticoagulation Knowledge Tool (AKT) can assess a patient’s knowledge about her/his oral anticoagulant therapy and can assist health professionals in identifying patients with difficulties in adherence. This study aimed to translate, culturally adapt, and validate the AKT into Brazilian Portuguese. After a standard forward-backward procedure to translate the AKT into Brazilian Portuguese (AKT-Br), a version of the instrument was applied in three groups (patients, pharmacists, and the general population). The reliability of the AKT-Br was tested using an internal consistency measure and test-retest. The validity of the instrument was confirmed with data from the contrasted groups. All statistical analyses were performed with RStudio. The median scores obtained with the AKT-Br were 29.0, 17.0, and 7.5 for pharmacists, patients, and the general population, respectively (maximum score of 35 points). There was moderate internal consistency for the instrument and test-retest reliability was satisfactory. Analysis of variance for validity of the groups revealed a significant relationship between the total score and the evaluated groups. The ATK-Br is a reliable and valid tool to assess knowledge about oral anticoagulants. AKT-Br can be used in clinical practice as an auxiliary tool to improve patient care through personalised educational interventions.
- 30 March 2021
- Published by Conselho Federal de Farmacia
Guia de prática clínica: sinais e sintomas respiratórios: tosse
- 30 March 2021
- Published by Conselho Federal de Farmacia
Guia de prática clínica: sinais e sintomas respiratórios: tosse
- 9 April 2019
- Published by Springer Nature in International Journal of Clinical Pharmacy
- Vol. 41 (3) , 785-792
Usability and sensitivity of the risk of bias assessment tool for randomized controlled trials of pharmacist interventions
Background The Cochrane collaboration risk of bias assessment (RoB) tool is used in several fields to evaluate the methodological quality of studies. Its strengths and challenges are discussed. Objective To assess the sensitivity of the RoB tool in studies of pharmacist interventions. Setting DEPICT database was used to pool randomized controlled trials (RCTs) of complex interventions. Method A Guide for RoB Judgment in Pharmacy Services was created to help in the interpretation and judgment of bias criteria. The evaluation of bias (low, unclear, high risk) was performed by RCT. Sensitivity analyses were performed to assess the influence of different interpretations of eight elements of judgment in the RoB tool. Paired analysis and estimations of the effect size (95% confidence interval) of the criteria modifications compared to the original analyses were calculated. Main outcome measure Changes in the interpretations of judgment in the RoB tool. Results Overall, 8.3, 45.4, and 46.3% of the studies were determined to have low, unclear, and high risk of bias, respectively. High risk of bias was caused by attrition and detection domains. The number of studies classified with high risk of bias significantly increased for five of the eight interpretations, while unclear risk of bias increased for three interpretations (with a negligible effect size in all of them). Lack of blinding, loss of participants, and the use of subjective and self-reported outcomes were the main elements resulting in high risk of bias. Conclusion The RoB tool is useful for evaluating RCTs of pharmacist interventions if adapted criteria for judgment are used. Ignoring these adjustments produces a floor-effect with studies classified with high risk of bias.
- 9 April 2019
- Published by Springer Nature in International Journal of Clinical Pharmacy
- Vol. 41 (3) , 785-792
Usability and sensitivity of the risk of bias assessment tool for randomized controlled trials of pharmacist interventions
Background The Cochrane collaboration risk of bias assessment (RoB) tool is used in several fields to evaluate the methodological quality of studies. Its strengths and challenges are discussed. Objective To assess the sensitivity of the RoB tool in studies of pharmacist interventions. Setting DEPICT database was used to pool randomized controlled trials (RCTs) of complex interventions. Method A Guide for RoB Judgment in Pharmacy Services was created to help in the interpretation and judgment of bias criteria. The evaluation of bias (low, unclear, high risk) was performed by RCT. Sensitivity analyses were performed to assess the influence of different interpretations of eight elements of judgment in the RoB tool. Paired analysis and estimations of the effect size (95% confidence interval) of the criteria modifications compared to the original analyses were calculated. Main outcome measure Changes in the interpretations of judgment in the RoB tool. Results Overall, 8.3, 45.4, and 46.3% of the studies were determined to have low, unclear, and high risk of bias, respectively. High risk of bias was caused by attrition and detection domains. The number of studies classified with high risk of bias significantly increased for five of the eight interpretations, while unclear risk of bias increased for three interpretations (with a negligible effect size in all of them). Lack of blinding, loss of participants, and the use of subjective and self-reported outcomes were the main elements resulting in high risk of bias. Conclusion The RoB tool is useful for evaluating RCTs of pharmacist interventions if adapted criteria for judgment are used. Ignoring these adjustments produces a floor-effect with studies classified with high risk of bias.
- Open Access
- 20 November 2014
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 78 (6) , 1465-1466
Critical assessment of the systematic review on hospitalization resulting from medicine related problems
- 20 November 2014
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 78 (6) , 1465-1466
Open AccessCritical assessment of the systematic review on hospitalization resulting from medicine related problems